Aratana Therapeutics, Inc. (PETX) to Release Quarterly Earnings on Wednesday
Aratana Therapeutics, Inc. (NASDAQ:PETX) is set to issue its quarterly earnings data after the market closes on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.
Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. The business had revenue of $5.16 million for the quarter, compared to analyst estimates of $4.50 million. Aratana Therapeutics had a negative net margin of 642.93% and a negative return on equity of 51.21%. The company’s revenue was down 86.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.61 EPS. On average, analysts expect Aratana Therapeutics to post $-1.1 EPS for the current fiscal year and $-0.57 EPS for the next fiscal year.
Shares of Aratana Therapeutics, Inc. (PETX) opened at 6.06 on Wednesday. Aratana Therapeutics, Inc. has a one year low of $4.97 and a one year high of $8.92. The firm has a 50-day moving average of $6.18 and a 200-day moving average of $6.28. The company’s market cap is $260.59 million.
In other news, insider Peter Steven St sold 50,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $6.24, for a total value of $312,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Brent Standridge sold 10,000 shares of the company’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $6.11, for a total transaction of $61,100.00. Following the completion of the transaction, the chief operating officer now owns 70,267 shares in the company, valued at $429,331.37. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 70,000 shares of company stock worth $435,600. Company insiders own 5.20% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/25/aratana-therapeutics-inc-petx-to-release-quarterly-earnings-on-wednesday-2.html.
PETX has been the topic of several recent analyst reports. ValuEngine downgraded shares of Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. BidaskClub downgraded shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research raised shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a research note on Tuesday, July 4th. Jefferies Group LLC set a $8.00 target price on shares of Aratana Therapeutics and gave the company a “buy” rating in a research note on Friday, August 4th. Finally, Lake Street Capital reduced their target price on shares of Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 25th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $8.25.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.